We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
RTI Surgical at a 52-Week High: What's Driving the Stock?
Read MoreHide Full Article
Share price of RTI Surgical, Inc. , based in Alachua, FL, scaled a new 52-week high of $6.00 on Jul 10, eventually closing a bit lower at $5.65. The company has witnessed a consistent rally in its share price, gaining around 39.5% since the announcement of impressive revenue performance in the first quarter of 2017.
Average volume of shares traded over the last one year was remarkable at approximately 268.5K. The stock has a market cap of $330.9 million.
Comparison with Broader Industry
For the majority of the last three months, the company’s share price has considerably outperformed the Zacks categorized Medical - Instruments sub-industry. The stock has rallied 44.9% over this period, outshining the sub-industry’s rise of 10.9%. The company has also outperformed the S&P 3.6% gain.
Taking the stable stock performance into consideration, we expect RTI Surgical to scale higher in the coming quarters.
Positive Surprise
This Zacks Rank #3 (Hold) company delivered a stellar four-quarter positive average earnings surprise of 25.00%.
Growth Catalysts
Investors are upbeat about the company’s recent announcement that it is now part of a U.S. public-private Manufacturing initiative, the Advanced Regenerative Manufacturing Institute (ARMI).ARMI will work under the umbrella of Manufacturing USA, a public-private network that invests in the development of advanced manufacturing technologies.
Also, we are encouraged to note that the company is focused on reducing cost by proper allocation of resources. The company has planned to invest more resources in profitable areas and less in the areas with lower growth potential. On the other hand the company is increasingly focusing on R&D investments.
Further, over the past one year, RTI Surgical has been gaining prominence on the back of the recent string of regulatory approvals. An advanced bone graft substitute of the company, nanOss Bioactive bone void filler, got approved by the Australian Therapeutic Goods Administration. The company has also announced CE Mark approval for nanOss Bioactive Loaded bone void filler and nanOss Bioactive 3D bone void filler in Europe.
The company’s impressive revenue performance in the first quarter of 2017, both in the domestic and international market, has also bolstered investors’ confidence in the stock.
Key Picks
A few better-ranked medical stocks are Mesa Laboratories, Inc. (MLAB - Free Report) , Edwards Lifesciences Corporation (EW - Free Report) and Align Technology, Inc. (ALGN - Free Report) . Notably, Mesa Laboratories and Edwards Lifesciences sport a Zacks Rank #1 (Strong Buy), while Align Technology carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Mesa Laboratories has a positive earnings surprise of 2.84% over the last four trailing quarters. The stock has added roughly 11.6% over the last three months.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has gained around 25.4% over the last three months.
Align Technology has an expected long-term adjusted earnings growth of almost 24.1%. The stock has added roughly 32.8% over the last three months.
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
RTI Surgical at a 52-Week High: What's Driving the Stock?
Share price of RTI Surgical, Inc. , based in Alachua, FL, scaled a new 52-week high of $6.00 on Jul 10, eventually closing a bit lower at $5.65. The company has witnessed a consistent rally in its share price, gaining around 39.5% since the announcement of impressive revenue performance in the first quarter of 2017.
Average volume of shares traded over the last one year was remarkable at approximately 268.5K. The stock has a market cap of $330.9 million.
Comparison with Broader Industry
For the majority of the last three months, the company’s share price has considerably outperformed the Zacks categorized Medical - Instruments sub-industry. The stock has rallied 44.9% over this period, outshining the sub-industry’s rise of 10.9%. The company has also outperformed the S&P 3.6% gain.
Taking the stable stock performance into consideration, we expect RTI Surgical to scale higher in the coming quarters.
Positive Surprise
This Zacks Rank #3 (Hold) company delivered a stellar four-quarter positive average earnings surprise of 25.00%.
Growth Catalysts
Investors are upbeat about the company’s recent announcement that it is now part of a U.S. public-private Manufacturing initiative, the Advanced Regenerative Manufacturing Institute (ARMI).ARMI will work under the umbrella of Manufacturing USA, a public-private network that invests in the development of advanced manufacturing technologies.
Also, we are encouraged to note that the company is focused on reducing cost by proper allocation of resources. The company has planned to invest more resources in profitable areas and less in the areas with lower growth potential. On the other hand the company is increasingly focusing on R&D investments.
RTI Surgical, Inc. Price and Consensus
RTI Surgical, Inc. Price and Consensus | RTI Surgical, Inc. Quote
Further, over the past one year, RTI Surgical has been gaining prominence on the back of the recent string of regulatory approvals. An advanced bone graft substitute of the company, nanOss Bioactive bone void filler, got approved by the Australian Therapeutic Goods Administration. The company has also announced CE Mark approval for nanOss Bioactive Loaded bone void filler and nanOss Bioactive 3D bone void filler in Europe.
The company’s impressive revenue performance in the first quarter of 2017, both in the domestic and international market, has also bolstered investors’ confidence in the stock.
Key Picks
A few better-ranked medical stocks are Mesa Laboratories, Inc. (MLAB - Free Report) , Edwards Lifesciences Corporation (EW - Free Report) and Align Technology, Inc. (ALGN - Free Report) . Notably, Mesa Laboratories and Edwards Lifesciences sport a Zacks Rank #1 (Strong Buy), while Align Technology carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Mesa Laboratories has a positive earnings surprise of 2.84% over the last four trailing quarters. The stock has added roughly 11.6% over the last three months.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has gained around 25.4% over the last three months.
Align Technology has an expected long-term adjusted earnings growth of almost 24.1%. The stock has added roughly 32.8% over the last three months.
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>